Survival Outcomes of Nonsmall Cell Lung Cancer Patients Treated with Afatinib Who Are Affected by Early Adverse Events

Table 1

Summary of the association between adverse events within the first 28 days of afatinib treatment and OS or PFS.

N		Overall survival			Progression free survival
		Median (months)	HR [95% CI]	value	Median (months)	HR [95% CI]	value
Stomatitis				0.631			0.476
0	222	27	1.00		11	1.00
1	165	25	1.12 [0.86–1.46]		11	0.95 [0.75–1.20]
2+	67	27	1.13 [0.80–1.60]		14	0.81 [0.58–1.14]
Rash				0.018			0.732
0	140	22	1.00		11	1.00
1	191	28	0.74 [0.56–0.97]		11	0.91 [0.71–1.18]
2+	123	33	0.64 [0.46–0.89]		13	0.90 [0.68–1.21]
Paronychia				0.232			0.112
0	396	26	1.00		11	1.00
1	36	31	0.84 [0.54–1.30]		11	0.85 [0.57–1.26]
2+	22	42	0.63 [0.34–1.17]		15	0.61 [0.36–1.03]
Diarrhoea				0.605			0.015
0	65	23	1.00		10	1.00
1	263	26	0.95 [0.68–1.33]		11	0.83 [0.62–1.12]
2+	126	31	0.84 [0.58–1.23]		14	0.62 [0.44–0.88]

HR = hazard ratio; CI = confidence interval.